Visual signs and symptoms of corticobasal degeneration

Armstrong, Richard A.

doi:10.1111/cxo.12429

Cited by 16 publications

(10 citation statements)

References 85 publications

(259 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, an outstanding question is to what extent ocular manifestations of PD can be differentiated from other parkinsonian syndromes, normal aging, and other neurodegenerative diseases. In a comparison of PD and MSA, corticobasal degeneration, progressive supranuclear palsy, and Lewy body dementia, Armstrong suggested predominantly differences in complex visual functions, such as visuospatial dysfunction, visual hallucinations, and event‐evoked potentials . Differences in the eye between PD and MSA have been reported, including RNFL thinning with preferential loss of M‐type RGCs in the MSA retina, with preservation of visual acuity and color vision in MSA when compared with PD …”

Section: Discussionmentioning

confidence: 99%

“…In a comparison of PD and MSA, corticobasal degeneration, progressive supranuclear palsy, and Lewy body dementia, Armstrong suggested predominantly differences in complex visual functions, such as visuospatial dysfunction, visual hallucinations, and event-evoked potentials. 28,[205][206][207][208][209] Differences in the eye between PD and MSA have been reported, including RNFL thinning with preferential loss of M-type RGCs in the MSA retina, with preservation of visual acuity and color vision in MSA when compared with PD. 206,210 We and others do not believe that the retinal biomarkers discussed in this manuscript are unique to PD/parkinsonism.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers

et al. 2018

View full text Add to dashboard Cite

Parkinson's disease (PD) is one of the most common neurodegenerative disorders and the second leading cause of dementia worldwide. With an aging population, the prevalence of the disease has dramatically increased. Clinical management has advanced through recent developments in dopaminergic imaging and genetic risk profiling. However, early and accurate diagnosis of the disorder remains a challenge, largely because of the lack of noninvasive and inexpensive reliable diagnostic tests. Besides the well‐studied cerebral neurodegeneration that underlies the cardinal symptoms of PD (ie, bradykinesia, tremor, rigidity, and postural instability), ocular changes have also been described in PD, including visual dysfunction, pupil abnormality, lens opacity, and retinal neuronal loss and dysfunction. These ocular pathological processes are related to α‐synuclein deposition, and dopamine deficiency in the retina—mirroring the defining pathological features of PD in the brain. Together, these observations support the notion that the eye can serve as a window to the brain, providing clinicians with noninvasive methods to visualize disease. This review focuses on recent advances in the characterization of ocular changes in PD and their promising use as biomarkers in the eye, which can be potentially used for aiding in early diagnosis, tracking disease progression, and valuating novel therapeutic strategies. © 2018 International Parkinson and Movement Disorder Society

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Abnormal eye movements were reported in 60% of CDB patients, but insufficient details were provided. Increased saccadic latency has been described in CBS 22,23 , but analysis of CBD patients failed to demonstrate this 24 .…”

Section: The Clinical Spectrum Associated With Corticobasal Degenerationmentioning

confidence: 97%

Cognitive dysfunction in corticobasal degeneration

Oliveira

Barcellos

Teive

et al. 2017

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Corticobasal degeneration (CBD) is a rare and progressive neurodegenerative disease. It was originally described as a distinct clinicopathological entity in 1967 1 and later recognized as a polymorphous disease due to its complexity. In fact, the classical set of symptoms -namely asymmetric motor features associated with higher cortical function -were found to be associated with multiple histological presentations. Furthermore, the distinctive histopathological findings of cortical and striatal neuronal deposition of tau, and glial inclusions, were also linked to a wide variety of clinical phenotypes 2 . Hence, recent literature refers to corticobasal syndrome (CBS) as the constellation of symptoms described originally, limiting CBD to the distinctive histopathological findings .The different terminology with a seemingly paradoxical intrinsic overlap between these conditions makes diagnosis challenging. For instance, only 25% to 56.25% of patients with pathologically-confirmed CBD had previously presented with symptoms of CBS 4,5,6 . On the other hand, the proportion of patients diagnosed with CBS presenting with the histologic hallmarks of CBD is highly variable, ranging from 23.8% to 100% 4,5,6,7 . Considering the enormous difficulty in accurately diagnosing CBD during life, it is clear that current ABSTRACTCorticobasal degeneration (CBD) was originally described as a distinct clinicopathological entity in 1967. Since then, different phenotypic presentations have emerged as possible manifestations of CBD histopathological findings. In addition, pathophysiological findings and the molecular basis have been delineated and several aspects of its cognitive manifestations have been clarified. Thus, not only the spectrum of what is currently designated as CBD has expanded, but overlap with other degenerative and even secondary disorders has made clinical diagnostic certainty even more challenging in the absence of specific and readily-available markers. Cognitive deficits in CBD are now recognized as a frequent initial presentation and may appear up to eight years before the motor symptoms, depending on the phenotypic variant. Characteristic cognitive features of CBD involve language deficits, visuospatial and executive dysfunctions, apraxia, and behavioral disorders. Semantic and episodic memories are usually preserved, while language is often impaired in the early stages.Keywords: dementia; cognition; corticobasal degeneration. RESUMOA degeneração corticobasal (DCB) foi originalmente descrita como uma entidade clínico-patológica distinta em 1967. Desde então, nossa compreensão sobre DCB evoluiu substancialmente. Diferentes apresentações fenotípicas emergiram refletindo possíveis manifestações das anormalidades histopatológicos da DCB. Adicionalmente, dados fisiopatológicos e moleculares foram delineados e aspectos das manifestações cognitivas foram explorados. Assim, não só o espectro do que é atualmente designado DCB foi expandido, mas a sobreposição com outras doenças degenerativas e até mesmo secundárias to...

show abstract

“…The term CBD refers to the deposition of abnormally hyperphosphorylated microtubule-associated tau protein in the somatosensory, premotor and supplementary motor cortices, as well as the brainstem and basal ganglia [62]. In most cases, CBS is a tauopathy but the disease is not always due to corticobasal degeneration, suggesting some clinicopathological heterogeneity [63]. The clinical syndrome of CBS is complex, characterized by limb clumsiness, marked asymmetrical parkinsonism-dystonia, apraxia, cortical deficits, myoclonus and dementia in various combinations [61].…”

Section: Corticobasal Syndromementioning

confidence: 99%

Gait and postural disorders in parkinsonism: a clinical approach

et al. 2019

View full text Add to dashboard Cite

Disturbances of balance, gait and posture are a hallmark of parkinsonian syndromes. Recognition of these axial features can provide important and often early clues to the nature of the underlying disorder, and, therefore, help to disentangle Parkinson's disease from vascular parkinsonism and various forms of atypical parkinsonism, including multiple system atrophy, progressive supranuclear palsy, and corticobasal syndrome. Careful assessment of axial features is also essential for initiating appropriate treatment strategies and for documenting the outcome of such interventions. In this article, we provide an overview of balance, gait and postural impairment in parkinsonian disorders, focusing on differential diagnostic aspects.

show abstract

Visual signs and symptoms of corticobasal degeneration

Cited by 16 publications

References 85 publications

Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers

Oculo‐visual abnormalities in Parkinson's disease: Possible value as biomarkers

Cognitive dysfunction in corticobasal degeneration

Gait and postural disorders in parkinsonism: a clinical approach

Contact Info

Product

Resources

About